Scratching the surface: Towards understanding the pathogenesis of atopic dermatitis

Critical Reviews in Immunology

Volumn 28, Issue 1, 2008, Pages 15-43

  Sehra, Sarita ^a   Tuana, Florencia M Barbé ^a   Holbreich, Mark ^a   Mousdicas, Nico ^a   Tepper, Robert S ^a   Chang, Cheong Hee ^b   Travers, Jeffrey B ^a   Kaplan, Mark H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Asthma; Atopic dermatitis; Atopic march; Eczema; Environmental; Eosinophils; Epidermal differentiation complex; Filaggrin; Genetic; IgE; Keratinocytes; Rhinitis; Skin barrier; T cells

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; ATOPICLAIR; CALCINEURIN INHIBITOR; CEFALEXIN; CERA VE; CICLOPIROXOLAMINE; COLECALCIFEROL; CORTICOSTEROID; CUTANEOUS T CELL ATTRACTING CHEMOKINE ANTIBODY; EOTAXIN; EPICREAM; FC EPSILON RECEPTOR 1BETA; FC RECEPTOR; FOOD ALLERGEN; HAPTEN; IMIDAZOPYRAZINE DERIVATIVE; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 7; MIMYX; MONTELUKAST; NEUTRALIZING ANTIBODY; OMALIZUMAB; PIMECROLIMUS; RANTES; RETAPAMULIN; RUPATADINE; STAT6 PROTEIN; TACROLIMUS; TAK 427; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRICREAM; UNCLASSIFIED DRUG;

ACNE; ALLERGY; ANTIGEN PRESENTING CELL; ATOPIC DERMATITIS; CAT; CREAM; DOG; EFFECTOR CELL; ENVIRONMENTAL FACTOR; EOSINOPHIL; EXPERIMENTAL MODEL; FOOD ALLERGY; GENE; GENE CLUSTER; GENETIC ENGINEERING; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOME; GUINEA PIG; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; KERATINOCYTE; MAST CELL; MEDIATOR; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RODENT; STRIA; T LYMPHOCYTE; TH2 CELL; TRANSGENIC MOUSE; TREATMENT PLANNING; YEAST;

ALLERGENS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BACTERIA; CYTOKINES; DERMATITIS, ATOPIC; FOOD HYPERSENSITIVITY; HUMANS; LYMPHOCYTES;

EID: 39349107858     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (254)

1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry crosssectional surveys. Lancet. 2006 Aug 26;368(9537): 733-43.
2. Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, Stricker T, Eigenmann PA, Braun-Fahrlander C. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006 May;61(5):556-62.
3. Wadonda-Kabondo N, Sterne JA, Golding J, Kennedy CT, Archer CB, Dunnill MG. A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0-42 months. Br J Dermatol. 2003 Nov;149(5):1023-8.
4. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, Asher I, Beasley R, Bjorksten B, Burr M, Clayton T, Crane J, Ellwood P, Keil U, Lai C, Mallol J, Martinez F, Mitchell E, Montefort S, Pearce N, Shah J, Sibbald B, Strachan D, von Mutius E, Weiland SK. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38.
5. Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol. 1992 Nov;17(6):385-91.
6. Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics. 2003;21(2):105-13.
7. Curtiss FR. Prevalence and costs of atopic dermatitis. J Manag Care Pharm. 2002 Sep-Oct;8(5):404.
8. Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Stevens SR, Whitaker-Worth DL, Cheng JW, Tong KB. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002 Mar;46(3):361-70.
9. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001 Mar;144(3):514-22.
10. Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol. 2004 Feb;45(1):16-22.
11. Ricci G, Bendandi B, Pagliara L, Patrizi A, Masi M. Atopic dermatitis in Italian children: evaluation of its economic impact. J Pediatr Health Care. 2006 Sep-Oct;20(5):311-5.
12. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997 Feb;76(2):159-62.
13. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol. 2002 Oct;147(4):716-24.
14. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006 Aug;60(8):984-92.
15. Hanifin JM. Ketoconazole - an oral antifungal with activity against superficial and deep mycoses. International Symposium, Medellin, Colombia, Nov. 28 and 29, 1979. J Am Acad Dermatol. 1980 Jun;2(6):537-9.
16. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004 Mar;113(5):651-7.
17. Johansson C, Tengvall Linder M, Aalberse RC, Scheynius A. Elevated levels of IgG and IgG4 to Malassezia allergens in atopic eczema patients with IgE reactivity to Malassezia. Int Arch Allergy Immunol. 2004 Oct;135(2):93-100.
18. Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999 Dec;104(6):1280-4.
19. Bergmann RL, Edenharter G, Bergmann KE, Forster J, Bauer CP, Wahn V, Zepp F, Wahn U. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy. 1998 Aug;28(8):965-70.
20. Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis - a prospective follow-up to 7 years of age. Allergy. 2000 Mar;55(3):240-5.
21. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003 Dec;112(6 Suppl):S118-27.
22. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol. 2004 Jul;114(1):150-8.
23. Kusel MM, Holt PG, de Klerk N, Sly PD. Support for 2 variants of eczema. J Allergy Clin Immunol. 2005 Nov;116(5):1067-72.
24. Olesen AB, Ellingsen AR, Olesen H, Juul S, Thestrup-Pedersen K. Atopic dermatitis and birth factors: historical follow up by record linkage. BMJ. 1997 Apr 5;314(7086):1003-8.
25. Williams HC. Atopic dermatitis: new information from epidemiological studies. Br J Hosp Med. 1994 Oct 19-Nov 1;52(8):409-12.
26. Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C, Schutze S, Proksch E. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol. 2004 Jun;122(6):1423-31.
27. Marekov LN, Steinert PM. Ceramides are bound to structural proteins of the human foreskin epidermal cornified cell envelope. J Biol Chem. 1998 Jul 10;273(28):17763-70.
28. Meguro S, Arai Y, Masukawa Y, Uie K, Tokimitsu I. Relationship between covalently bound ceramides and transepidermal water loss (TEWL). Arch Dermatol Res. 2000 Sep;292(9):463-8.
29. Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM, Feingold KR. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. 2005 Mar;124(3):587-95.
30. Denda M, Tsuchiya T, Elias PM, Feingold KR. Stress alters cutaneous permeability barrier homeostasis. Am J Physiol Regul Integr Comp Physiol. 2000 Feb;278(2):R367-72.
31. Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW, Ward SJ, Tazi-Ahnini R. Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol. 2004 Jul;123(1):62-6.
32. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol. 2006 Jul;118(1):3-21; quiz 2-3.
33. Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE, Coleman R, Leaves NI, Trembath RC, Moffatt MF, Harper JI. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet. 2001 Apr;27(4):372-3.
34. Marshall D, Hardman MJ, Nield KM, Byrne C. Differentially expressed late constituents of the epidermal cornified envelope. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13031-6.
35. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. J Invest Dermatol. 1996 May;106(5):989-92.
36. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006 Apr;38(4):441-6.
37. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006 Mar;38(3):337-42.
38. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40.
39. Weidinger S, Rodriguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T, Novak N. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol. 2007 Mar;127(3):724-6.
40. Patrizi A, Guerrini V, Ricci G, Neri I, Specchia F, Masi M. The natural history of sensitizations to food and aeroallergens in atopic dermatitis: a 4-year follow-up. Pediatr Dermatol. 2000 Jul-Aug;17(4):261-5.
41. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines." J Am Acad Dermatol. 2004 Mar;50(3):391-404.
42. Hanifin JM. Critical evaluation of food and mite allergy in the management of atopic dermatitis. J Dermatol. 1997 Aug;24(8):495-503.
43. Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol. 1999 May;103(5 Pt 1):717-28.
44. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics. 1998 Mar;101(3):E8.
45. Sampson HA. The evaluation and management of food allergy in atopic dermatitis. Clin Dermatol. 2003 May-Jun;21(3):183-92.
46. Burks AW, James JM, Hiegel A, Wilson G, Wheeler JG, Jones SM, Zuerlein N. Atopic dermatitis and food hypersensitivity reactions. J Pediatr. 1998 Jan;132(1):132-6.
47. Gutgesell C, Heise S, Seubert S, Seubert A, Domhof S, Brunner E, Neumann C. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol. 2001 Jul;145(1):70-4.
48. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996 Jan 6;347(8993):15-8.
49. Boguniewicz M, Leung DY. 10. Atopic dermatitis. J Allergy Clin Immunol. 2006 Feb;117(2 Suppl Mini-Primer):S475-80.
50. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006 Jul;118(1):40-3.
51. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003 Jan 11;361(9352):151-60.
52. Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr. 2003 Aug;15(4):399-404.
53. de Vries IJ, Langeveld-Wildschut EG, van Reijsen FC, Dubois GR, van den Hoek JA, Bihari IC, van Wichen D, de Weger RA, Knol EF, Thepen T, Bruijnzeel-Koomen CA. Adhesion molecule expression on skin endothelia in atopic dermatitis: effects of TNF-alpha and IL-4. J Allergy Clin Immunol. 1998 Sep;102(3):461-8.
54. Bunikowski R, Mielke M, Skarabis H, Herz U, Bergmann RL, Wahn U, Renz H. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):119-24.
55. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol. 1994 Apr;30(4):535-46.
56. Nomura I, Tanaka K, Tomita H, Katsunuma T, Ohya Y, Ikeda N, Takeda T, Saito H, Akasawa A. Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):441-6.
57. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, Leung DY. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity. 2006 Mar;24(3):341-8.
58. Kim BE, Leung DY, Streib JE, Boguniewicz M, Hamid QA, Howell MD. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J Allergy Clin Immunol. 2007 Feb;119(2):457-63.
59. Jensen-Jarolim E, Poulsen LK, With H, Kieffer M, Ottevanger V, Stahl Skov P. Atopic dermatitis of the face, scalp, and neck: type I reaction to the yeast Pityrosporum ovale? J Allergy Clin Immunol. 1992 Jan;89(1 Pt 1):44-51.
60. Kolmer HL, Taketomi EA, Hazen KC, Hughs E, Wilson BB, Platts-Mills TA. Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis. J Allergy Clin Immunol. 1996 Sep;98(3):702-7.
61. Back O, Scheynius A, Johansson SG. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res. 1995;287(5):448-51.
62. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002 Oct 10;347(15):1151-60.
63. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature. 1997 Jun 26;387(6636):861.
64. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem. 2001 Feb 23;276(8):5707-13.
65. Harder J, Siebert R, Zhang Y, Matthiesen P, Christophers E, Schlegelberger B, Schroder JM. Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics. 1997 Dec 15;46(3):472-5.
66. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB Jr, Tack BF, Vogel HJ. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem. 2002 Mar 8;277(10):8279-89.
67. Midorikawa K, Ouhara K, Komatsuzawa H, Kawai T, Yamada S, Fujiwara T, Yamazaki K, Sayama K, Taubman MA, Kurihara H, Hashimoto K, Sugai M. Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun. 2003 Jul;71(7):3730-9.
68. Maisetta G, Batoni G, Esin S, Raco G, Bottai D, Favilli F, Florio W, Campa M. Susceptibility of Streptococcus mutans and Actinobacillus actinomycetemcomitans to bactericidal activity of human beta-defensin 3 in biological fluids. Antimicrob Agents Chemother. 2005 Mar;49(3):1245-8.
69. Howell MD, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G, Leung DY. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol. 2006 Dec;121(3):332-8.
70. Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M, Streib J, Wong C, Gallo RL, Leung DY. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol. 2005 Oct;125(4):738-45.
71. Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol. 2006 Jul;118(1):178-89.
72. Aioi A, Tonogaito H, Suto H, Hamada K, Ra CR, Ogawa H, Maibach H, Matsuda H. Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis. Br J Dermatol. 2001 Jan;144(1):12-8.
73. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW, Ra C. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/ Nga mice. Int Immunol. 1997 Mar;9(3):461-6.
74. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, Imai T, Yoshie O, Irimura T, Mizutani H, Matsushima K. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest. 1999 Oct;104(8):1097-105.
75. Sasakawa T, Higashi Y, Sakuma S, Hirayama Y, Sasakawa Y, Ohkubo Y, Goto T, Matsumoto M, Matsuda H. Atopic dermatitis-like skin lesions induced by topical application of mite antigens in NC/ Nga mice. Int Arch Allergy Immunol. 2001 Nov;126(3):239-47.
76. Matsumoto M, Ra C, Kawamoto K, Sato H, Itakura A, Sawada J, Ushio H, Suto H, Mitsuishi K, Hikasa Y, Matsuda H. IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J Immunol. 1999 Jan 15;162(2):1056-63.
77. Shiohara T, Hayakawa J, Mizukawa Y. Animal models for atopic dermatitis: are they relevant to human disease? J Dermatol Sci. 2004 Oct;36(1):1-9.
78. Gutermuth J, Ollert M, Ring J, Behrendt H, Jakob T. Mouse models of atopic eczema critically evaluated. Int Arch Allergy Immunol. 2004 Nov;135(3):262-76.
79. Yagi R, Nagai H, Iigo Y, Akimoto T, Arai T, Kubo M. Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. J Immunol. 2002 Feb 15;168(4):2020-7.
80. Tenda Y, Yamashita M, Kimura MY, Hasegawa A, Shimizu C, Kitajima M, Onodera A, Suzuki A, Seki N, Nakayama T. Hyperresponsive TH2 cells with enhanced nuclear factor-kappa B activation induce atopic dermatitis-like skin lesions in Nishiki-nezumi Cinnamon/Nagoya mice. J Allergy Clin Immunol. 2006 Sep;118(3):725-33.
81. Kohara Y, Tanabe K, Matsuoka K, Kanda N, Matsuda H, Karasuyama H, Yonekawa H. A major determinant quantitative-trait locus responsible for atopic dermatitis-like skin lesions in NC/Nga mice is located on Chromosome 9. Immunogenetics. 2001 Feb;53(1):15-21.
82. Sakai T, Kogiso M, Mitsuya K, Komatsu T, Yamamoto S. Defect of toll-like receptor 9-mediated activation in NC/Nga mouse macrophages. Immunol Lett. 2006 Jul 15;106(1):91-5.
83. Yamamoto M, Haruna T, Yasui K, Takahashi H, Iduhara M, Takaki S, Deguchi M, Arimura A. A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/ Nga mice. Allergol Int. 2007 Jun;56(2):139-48.
84. Sawada J, Morita H, Tanaka A, Salminen S, He F, Matsuda H. Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy. 2007 Feb;37(2):296-303.
85. Petersen TK. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):104-15.
86. Li XM, Kleiner G, Huang CK, Lee SY, Schofield B, Soter NA, Sampson HA. Murine model of atopic dermatitis associated with food hypersensitivity. J Allergy Clin Immunol. 2001 Apr;107(4):693-702.
87. Marsella R, Olivry T. Animal models of atopic dermatitis. Clin Dermatol. 2003 Mar-Apr;21(2):122-33.
88. Jones SM, Sampson HA. The role of allergens in atopic dermatitis. Clin Rev Allergy. 1993 Winter;11(4):471-90.
89. He R, Oyoshi MK, Jin H, Geha RS. Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15817-22. Epub 2007 Sep 24.
90. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest. 1998 Apr 15;101(8):1614-22.
91. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest. 1999 Apr;103(8):1103-11.
92. Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, Nakanishi K, Clark S, Kurimoto M, Okamura H, Fujiwara H. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol. 1997 Sep 1;159(5):2125-31.
93. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity. 1997 Oct;7(4):571-81.
94. Konishi H, Tsutsui H, Murakami T, Yumikura-Futatsugi S, Yamanaka K, Tanaka M, Iwakura Y, Suzuki N, Takeda K, Akira S, Nakanishi K, Mizutani H. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11340-5.
95. Lee GR, Flavell RA. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol. 2004 Aug;16(8):1155-60.
96. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001 Oct;117(4):977-83.
97. Chen L, Martinez O, Venkataramani P, Lin SX, Prabhakar BS, Chan LS. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol. 2005 Feb;139(2):189-201.
98. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, Chan LS. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol. 2004 Dec;138(3):375-87.
99. Chen L, Lin SX, Agha-Majzoub R, Overbergh L, Mathieu C, Chan LS. CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model. Int Immunol. 2006 Aug;18(8):1233-42.
100. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, Copeland NG, Jenkins NA, McEvoy LM, Zlotnik A. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5.
101. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002 Feb;8(2):157-65.
102. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E, Zlotnik A. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol. 2000 Apr 1;164(7):3465-70.
103. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, Knol E. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004 Feb;113(2):334-40.
104. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. Clin Exp Dermatol. 2004 May;29(3):293-6.
105. Moed H, Boorsma DM, Tensen CP, Flier J, Jonker MJ, Stoof TJ, von Blomberg BM, Bruynzeel DP, Scheper RJ, Rustemeyer T, Gibbs S. Increased CCL27-CCR10 expression in allergic contact dermatitis: implications for local skin memory. J Pathol. 2004 Sep;204(1):39-46.
106. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004 Jul;5(7):752-60.
107. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006 Feb;117(2):411-7.
108. Tsunemi Y, Saeki H, Nakamura K, Nagakubo D, Nakayama T, Yoshie O, Kagami S, Shimazu K, Kadono T, Sugaya M, Komine M, Matsushima K, Tamaki K. CCL17 transgenic mice show an enhanced Th2-type response to both allergic and non-allergic stimuli. Eur J Immunol. 2006 Aug;36(8):2116-27.
109. Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol. 2007 Jun;28(6):248-51.
110. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med. 2006 Feb 20;203(2):269-73.
111. Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt Rde W, Omori M, Zhou B, Ziegler SF. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219.
112. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, Comeau MR, Campbell DJ, Ziegler SF. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005 Aug 15;202(4):541-9.
113. Li M, Hener P, Zhang Z, Kato S, Metzger D, Chambon P. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11736-41.
114. Bruns HA, Schindler U, Kaplan MH. Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol. 2003 Apr 1;170(7):3478-87.
115. Asakawa M, Yoshioka T, Hikita I, Matsutani T, Hirasawa T, Arimura A, Sakata T, Horikawa T. WBN/ Kob-Ht rats spontaneously develop dermatitis under conventional conditions: another possible model for atopic dermatitis. Exp Anim. 2005 Oct;54(5):461-5.
116. Hikita I, Yoshioka T, Mizoguchi T, Tsukahara K, Tsuru K, Nagai H, Hirasawa T, Tsuruta Y, Suzuki R, Ichihashi M, Horikawa T. Characterization of dermatitis arising spontaneously in DS-Nh mice maintained under conventional conditions: another possible model for atopic dermatitis. J Dermatol Sci. 2002 Nov;30(2):142-53.
117. Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, Hamid Q. Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):645-50.
118. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974 May;90(5):525-30.
119. Roosje PJ, Dean GA, Willemse T, Rutten VP, Thepen T. Interleukin 4-producing CD4+ T cells in the skin of cats with allergic dermatitis. Vet Pathol. 2002 Mar;39(2):228-33.
120. Sampson HA. Pathogenesis of eczema. Clin Exp Allergy. 1990 Sep;20(5):459-67.
121. Yoshioka T, Hikita I, Matsutani T, Yoshida R, Asakawa M, Toyosaki-Maeda T, Hirasawa T, Suzuki R, Arimura A, Horikawa T. DS-Nh as an experimental model of atopic dermatitis induced by Staphylococcus aureus producing staphylococcal enterotoxin C. Immunology. 2003 Apr;108(4):562-9.
122. Neckermann G, Bavandi A, Meingassner JG. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol. 2000 Apr;142(4):669-79.
123. Bavandi A, Meingassner JG, Becker S. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. Exp Dermatol. 1992 Nov;1(4):199-205.
124. Saurat JH, Chavez P, Ponvert C, Galloppin L. Skin inflammation induced by hypomagnesaemia in the rat. Br J Dermatol. 1983 Jul;109 Suppl 25:106-10.
125. Ponvert C, Galoppin L, Saurat JH. The dermatosis of hairless rats fed a hypomagnesaemic diet. I. Course, clinical features and inhibition by drugs. Clin Exp Dermatol. 1983 Sep;8(5):539-47.
126. Classen CU, Abele C, Schimatschek HF, Friedberg KD, Classen HG, Haubold W. Erythema formation in magnesium-deficient albino rats. A non-invasive model for the screening of anti-inflammatory agents and oral mineral supplements. Arzneimittelforschung. 1993 Jun;43(6):672-5.
127. Fukuda S, Midoro K, Kamei T, Gyoten M, Kawano Y, Ashida Y, Nagaya H. Inhibition of allergic dermal inflammation by the novel imidazopyridazine derivative TAK-427 in a guinea pig experimental model of eczema. J Pharmacol Exp Ther. 2002 Dec;303(3):1283-90.
128. Saloga J, Leung DY, Reardon C, Giorno RC, Born W, Gelfand EW. Cutaneous exposure to the superantigen staphylococcal enterotoxin B elicits a T-cell-dependent inflammatory response. J Invest Dermatol. 1996 May;106(5):982-8.
129. Feijen M, Gerritsen J, Postma DS. Genetics of allergic disease. Br Med Bull. 2000;56(4):894-907.
130. Hillier A, Griffin CE. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):147-51.
131. Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):255-69.
132. Butler JM, Peters JE, Hirshman CA, White CR Jr, Margolin LB, Hanifin JM. Pruritic dermatitis in asthmatic basenji-greyhound dogs: a model for human atopic dermatitis. J Am Acad Dermatol. 1983 Jan;8(1):33-8.
133. Nuttall TJ, Knight PA, McAleese SM, Lamb JR, Hill PB. Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis. Clin Exp Allergy. 2002 May;32(5):789-95.
134. Nimmo Wilkie JS, Yager JA, Wilkie BN, Parker WM. Abnormal cutaneous response to mitogens and a contact allergen in dogs with atopic dermatitis. Vet Immunol Immunopathol. 1991 Apr;28(2):97-106.
135. Olivry T, Naydan DK, Moore PF. Characterization of the cutaneous inflammatory infiltrate in canine atopic dermatitis. Am J Dermatopathol. 1997 Oct;19(5):477-86.
136. Sinke JD, Thepen T, Bihari IC, Rutten VP, Willemse T. Immunophenotyping of skin-infiltrating T-cell subsets in dogs with atopic dermatitis. Vet Immunol Immunopathol. 1997 Jun;57(1-2):13-23.
137. Olivry T, Moore PF, Affolter VK, Naydan DK. Langerhans cell hyperplasia and IgE expression in canine atopic dermatitis. Arch Dermatol Res. 1996 Sep;288(10):579-85.
138. Halliwell RE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (III): the role of antibodies in canine atopic dermatitis. Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):159-67.
139. Masuda K, Sakaguchi M, Fujiwara S, Kurata K, Yamashita K, Odagiri T, Nakao Y, Matsuki N, Ono K, Watari T, Hasegawa A, Tsujimoto H. Positive reactions to common allergens in 42 atopic dogs in Japan. Vet Immunol Immunopathol. 2000 Feb 25;73(2):193-204.
140. Mueller RS, Bettenay SV, Tideman L. Aero-allergens in canine atopic dermatitis in southeastern Australia based on 1000 intradermal skin tests. Aust Vet J. 2000 Jun;78(6):392-9.
141. Schick RO, Fadok VA. Responses of atopic dogs to regional allergens: 268 cases (1981-1984). J Am Vet Med Assoc. 1986 Dec 1;189(11):1493-6.
142. Nuttall TJ, Hill PB, Bensignor E, Willemse T. House dust and forage mite allergens and their role in human and canine atopic dermatitis. Vet Dermatol. 2006 Aug;17(4):223-35.
143. Leung DY. Atopic dermatitis and the immune system: the role of superantigens and bacteria. J Am Acad Dermatol. 2001 Jul;45(1 Suppl):S13-6.
144. DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XVI): laboratory evaluation of dogs with atopic dermatitis with serum-based "allergy" tests. Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):277-87.
145. McEwan NA. Adherence by Staphylococcus intermedius to canine keratinocytes in atopic dermatitis. Res Vet Sci. 2000 Jun;68(3):279-83.
146. Foil CS. Differential diagnosis of feline pruritus. Vet Clin North Am Small Anim Pract. 1988 Sep;18(5):999-1011.
147. Foster AP, O'Dair HA, DeBoer DJ. Allergen-specific IgG antibodies in cats with allergic skin disease. Res Vet Sci. 1997 Nov-Dec;63(3):239-43.
148. Gilbert S, Halliwell RE. Feline immunoglobulin E: induction of antigen-specific antibody in normal cats and levels in spontaneously allergic cats. Vet Immunol Immunopathol. 1998 May 29;63(3):235-52.
149. Fokkens WJ, Bruijnzeel-Koomen CA, Vroom TM, Rijntjes E, Hoefsmit EC, Mudde GC, Bruijnzeel PL. The Langerhans cell: an underestimated cell in atopic disease. Clin Exp Allergy. 1990 Nov;20(6):627-38.
150. Leung DY, Schneeberger EE, Siraganian RP, Geha RS, Bhan AK. The presence of IgE on macrophages and dendritic cells infiltrating into the skin lesion of atopic dermatitis. Clin Immunol Immunopathol. 1987 Mar;42(3):328-37.
151. Roosje PJ, Whitaker-Menezes D, Goldschmidt MH, Moore PF, Willemse T, Murphy GF. Feline atopic dermatitis. A model for Langerhans cell participation in disease pathogenesis. Am J Pathol. 1997 Oct;151(4):927-32.
152. Roosje PJ, van Kooten PJ, Thepen T, Bihari IC, Rutten VP, Koeman JP, Willemse T. Increased numbers of CD4+ and CD8+ T cells in lesional skin of cats with allergic dermatitis. Vet Pathol. 1998 Jul;35(4):268-73.
153. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol. 2001 Jan;44(1 Suppl):S1-S12.
154. Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today. 1998 Aug;19(8):359-61.
155. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994 Aug;94(2):870-6.
156. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996 Jul;98(1):225-31.
157. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P, Fukuda T, Elias JA, Hamid QA. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol. 2003 Apr;111(4):875-81.
158. Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. 2007 Dec;122(4):532-41. Epub 2007 Jul 11.
159. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998 Sep 1;334 (Pt 2):297-314.
160. Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem. 2007 Feb 2;282(5):3014-26.
161. Lin W, Truong N, Grossman WJ, Haribhai D, Williams CB, Wang J, Martin MG, Chatila TA. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol. 2005 Nov;116(5):1106-15.
162. Elkhal A, Pichavant M, He R, Scott J, Meyer E, Goya S, Geha RS, Umetsu DT. CD1d restricted natural killer T cells are not required for allergic skin inflammation. J Allergy Clin Immunol. 2006 Dec;118(6):1363-8.
163. Woodward AL, Spergel JM, Alenius H, Mizoguchi E, Bhan AK, Castigli E, Brodeur SR, Oettgen HC, Geha RS. An obligate role for T-cell receptor alphabeta+ T cells but not T-cell receptor gammadelta+ T cells, B cells, or CD40/CD40L interactions in a mouse model of atopic dermatitis. J Allergy Clin Immunol. 2001 Feb;107(2):359-66.
164. Laouini D, Alenius H, Bryce P, Oettgen H, Tsitsikov E, Geha RS. IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. J Clin Invest. 2003 Oct;112(7):1058-66.
165. Seneviratne SL, Jones L, Bailey AS, Black AP, Ogg GS. Severe atopic dermatitis is associated with a reduced frequency of IL-10 producing allergen-specific CD4+ T cells. Clin Exp Dermatol. 2006 Sep;31(5):689-94.
166. Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P, Prescott SL. Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-gamma responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy. 2005 Oct;35(10):1309-17.
167. Gombert M, Dieu-Nosjean MC, Winterberg F, Bunemann E, Kubitza RC, Da Cunha L, Haahtela A, Lehtimaki S, Muller A, Rieker J, Meller S, Pivarcsi A, Koreck A, Fridman WH, Zentgraf HW, Pavenstadt H, Amara A, Caux C, Kemeny L, Alenius H, Lauerma A, Ruzicka T, Zlotnik A, Homey B. CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol. 2005 Apr 15;174(8):5082-91.
168. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res. 2001 Jul;293(7):350-5.
169. Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Nakamura K, Takekoshi T, Kishimoto M, Mitsui H, Torii H, Komine M, Asahina A, Tamaki K. Significant elevation of serum levels of eotaxin-3/ CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol. 2003 Nov;134(2):309-13.
170. Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol. 2002 Sep;110(3):404-9.
171. Lin L, Nonoyama S, Oshiba A, Kabasawa Y, Mizutani S. TARC and MDC are produced by CD40 activated human B cells and are elevated in the sera of infantile atopic dermatitis patients. J Med Dent Sci. 2003 Mar;50(1):27-33.
172. Nakayama T, Fujisawa R, Yamada H, Horikawa T, Kawasaki H, Hieshima K, Izawa D, Fujiie S, Tezuka T, Yoshie O. Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/ macrophage inflammatory protein (MIP)-3 alpha/ CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol. 2001 Jan;13(1):95-103.
173. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005 Jun;152(6):1173-81.
174. Pivarcsi A, Gombert M, Dieu-Nosjean MC, Lauerma A, Kubitza R, Meller S, Rieker J, Muller A, Da Cunha L, Haahtela A, Sonkoly E, Fridman WH, Alenius H, Kemeny L, Ruzicka T, Zlotnik A, Homey B. CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol. 2004 Nov 1;173(9):5810-7.
175. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci. 2004 May;34(3):201-8.
176. Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A, Muro S, Toda M, Hamid QA. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol. 2000 May;105(5):1002-7.
177. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med. 2001 Nov 19;194(10):1541-7.
178. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000 Feb;12(2):121-7.
179. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/ American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006 Aug;61(8):969-87.
180. Novak N, Valenta R, Bohle B, Laffer S, Haberstok J, Kraft S, Bieber T. FcepsilonRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol. 2004 May;113(5):949-57.
181. Novak N, Allam JP, Hagemann T, Jenneck C, Laffer S, Valenta R, Kochan J, Bieber T. Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 2004 Aug;114(2):364-70.
182. Pastore S, Corinti S, La Placa M, Didona B, Girolomoni G. Interferon-gamma promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):538-44.
183. Yamada H, Matsukura M, Yudate T, Chihara J, Stingl G, Tezuka T. Enhanced production of RANTES, an eosinophil chemoattractant factor, by cytokine-stimulated epidermal keratinocytes. Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:28-32.
184. Bratton DL, Hamid Q, Boguniewicz M, Doherty DE, Kailey JM, Leung DY. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. J Clin Invest. 1995 Jan;95(1):211-8.
185. Pastore S, Fanales-Belasio E, Albanesi C, Chinni LM, Giannetti A, Girolomoni G. Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. J Clin Invest. 1997 Jun 15;99(12):3009-17.
186. Sayama K, Komatsuzawa H, Yamasaki K, Shirakata Y, Hanakawa Y, Ouhara K, Tokumaru S, Dai X, Tohyama M, Ten Dijke P, Sugai M, Ichijo H, Hashimoto K. New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of beta-defensins, LL37, and TLR2. Eur J Immunol. 2005 Jun;35(6):1886-95.
187. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brocker EB, Blaser K, Akdis CA. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000 Jul;106(1):25-35.
188. Galli SJ, Wedemeyer J, Tsai M. Analyzing the roles of mast cells and basophils in host defense and other biological responses. Int J Hematol. 2002 May;75(4):363-9.
189. Kobayashi H, Ishizuka T, Okayama Y. Human mast cells and basophils as sources of cytokines. Clin Exp Allergy. 2000 Sep;30(9):1205-12.
190. Alenius H, Laouini D, Woodward A, Mizoguchi E, Bhan AK, Castigli E, Oettgen HC, Geha RS. Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergen-induced skin inflammation. J Allergy Clin Immunol. 2002 Jan;109(1):106-13.
191. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004 Jan;146(1-2):1-12.
192. Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, Ziegler SF, Sarfati M, Delespesse G. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007 Feb 19;204(2):253-8.
193. Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis - eosinophil granule proteins as markers of disease activity. Allergy. 1993 Jan;48(1):1-5.
194. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004 Jun;59(6):561-70.
195. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med. 1992 Dec 1;176(6):1489-95.
196. Conus S, Bruno A, Simon HU. Leptin is an eosinophil survival factor. J Allergy Clin Immunol. 2005 Dec;116(6):1228-34.
197. Wong CK, Cheung PF, Lam CW. Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation. Eur J Immunol. 2007 Aug;37(8):2337-48.
198. Goodwin JS. Immunomodulation by eicosanoids and anti-inflammatory drugs. Curr Opin Immunol. 1989 Dec;2(2):264-8.
199. Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol. 1983;1:335-59.
200. Arai I, Takano N, Hashimoto Y, Futaki N, Sugimoto M, Takahashi N, Inoue T, Nakaike S. Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol. 2004 Nov 28;505(1-3):229-35.
201. Walterscheid JP, Ullrich SE, Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med. 2002 Jan 21;195(2):171-9.
202. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat. 2007 May;83(3):188-97.
203. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol. 2001 Jan;44(1):89-93.
204. Grandel KE, Farr RS, Wanderer AA, Eisenstadt TC, Wasserman SI. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med. 1985 Aug 15;313(7):405-9.
205. Travers JB, Murphy RC, Johnson CA, Pei Y, Morin SM, Clay KL, Barber LA, Hood AF, Morelli JG, Williams DA. Identification and pharmacological characterization of platelet-activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. Prostaglandins Other Lipid Mediat. 1998 Aug;56(5-6):305-24.
206. Jenks PJ, Kavanagh GM, Brooks J, Bradfield JW, Archer CB. Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Clin Exp Dermatol. 1999 Mar;24(2):112-7.
207. Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, Watanabe N, Fueki N, McIntyre TM, Zimmerman GA, Makino S, Prescott SM. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest. 1999 Apr;103(7):989-97.
208. Lemjabbar H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med. 2002 Jan;8(1):41-6.
209. Zhang Q, Mousdicas N, Yi Q, Al-Hassani M, Billings SD, Perkins SM, Howard KM, Ishii S, Shimizu T, Travers JB. Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor. J Clin Invest. 2005 Oct;115(10):2855-61.
210. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67(3):457-74.
211. Cookson WO, Moffatt MF. The genetics of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2002 Oct;2(5):383-7.
212. Duffy DL, Martin NG, Battistutta D, Hopper JL, Mathews JD. Genetics of asthma and hay fever in Australian twins. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1351-8.
213. Larsen FS, Holm NV, Henningsen K. Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol. 1986 Sep;15(3):487-94.
214. Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol. 1993 May;28(5 Pt 1):719-23.
215. Morar N, Willis-Owen SA, Moffatt MF, Cookson WO. The genetics of atopic dermatitis. J Allergy Clin Immunol. 2006 Jul;118(1):24-34; quiz 5-6.
216. Bradley M, Soderhall C, Luthman H, Wahlgren CF, Kockum I, Nordenskjold M. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet. 2002 Jun 15;11(13):1539-48.
217. Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, Tan Q, Kruse TA. Atopic dermatitis - a total genome-scan for susceptibility genes. Acta Derm Venereol. 2004;84(5):346-52.
218. Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson D, Andersson F, Oranje AP, Wolkertstorfer A, v Berg A, Hoffmann U, Kuster W, Wienker T, Ruschendorf F, Reis A. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet. 2000 Dec;26(4):470-3.
219. Zhang Y, Leaves NI, Anderson GG, Ponting CP, Broxholme J, Holt R, Edser P, Bhattacharyya S, Dunham A, Adcock IM, Pulleyn L, Barnes PJ, Harper JI, Abecasis G, Cardon L, White M, Burton J, Matthews L, Mott R, Ross M, Cox R, Moffatt MF, Cookson WO. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet. 2003 Jun;34(2):181-6.
220. Cookson WO, Sharp PA, Faux JA, Hopkin JM. Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q. Lancet. 1989 Jun 10;1(8650):1292-5.
221. Young RP, Sharp PA, Lynch JR, Faux JA, Lathrop GM, Cookson WO, Hopkin JM. Confirmation of genetic linkage between atopic IgE responses and chromosome 11q13. J Med Genet. 1992 Apr;29(4):236-8.
222. Hill MR, Cookson WO. A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. Hum Mol Genet. 1996 Jul;5(7):959-62.
223. Hill MR, James AL, Faux JA, Ryan G, Hopkin JM, le Souef P, Musk AW, Cookson WO. Fc epsilon RI-beta polymorphism and risk of atopy in a general population sample. BMJ. 1995 Sep 23;311(7008):776-9.
224. Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, Enomoto T, Hashimoto T, Furuyama J, Hopkin JM, Morimoto K. Association between genetic variants of mast-cell chymase and eczema. Lancet. 1996 Aug 31;348(9027):581-3.
225. Cox HE, Moffatt MF, Faux JA, Walley AJ, Coleman R, Trembath RC, Cookson WO, Harper JI. Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor. Br J Dermatol. 1998 Jan;138(1):182-7.
226. Bai B, Tanaka K, Tazawa T, Yamamoto N, Sugiura H. Association between RANTES promoter polymorphism -401A and enhanced RANTES production in atopic dermatitis patients. J Dermatol Sci. 2005 Sep;39(3):189-91.
227. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, Asano N, Tanida Y, Kakinuma T, Wakugawa M, Torii H, Tamaki K. Eotaxin gene single nucleotide polymorphisms in the promoter and exon regions are not associated with susceptibility to atopic dermatitis, but two of them in the promoter region are associated with serum IgE levels in patients with atopic dermatitis. J Dermatol Sci. 2002 Sep;29(3):222-8.
228. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafe JL, Wilkinson J, Taieb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000 Jun;25(2):141-2.
229. Magert HJ, Standker L, Kreutzmann P, Zucht HD, Reinecke M, Sommerhoff CP, Fritz H, Forssmann WG. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem. 1999 Jul 30;274(31):21499-502.
230. Kabesch M, Carr D, Weiland SK, von Mutius E. Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample. Clin Exp Allergy. 2004 Mar;34(3):340-5.
231. Kato A, Fukai K, Oiso N, Hosomi N, Murakami T, Ishii M. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol. 2003 Apr;148(4):665-9.
232. Nishio Y, Noguchi E, Shibasaki M, Kamioka M, Ichikawa E, Ichikawa K, Umebayashi Y, Otsuka F, Arinami T. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun. 2003 Oct;4(7):515-7.
233. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, Wong K, Abecasis GR, Jones EY, Harper JI, Hovnanian A, Cookson WO. Gene polymorphism in Netherton and common atopic disease. Nat Genet. 2001 Oct;29(2):175-8.
234. Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A, Klopp N, Wagenpfeil S, Zhao Y, Liao H, Lee SP, Palmer CN, Jenneck C, Maintz L, Hagemann T, Behrendt H, Ring J, Nothen MM, McLean WH, Novak N. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006 Jul;118(1):214-9.
235. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol. 2007 Jun;127(6):1282-4.
236. Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, Ota M, Sugiura H, Yamamoto K, Sato H, Palmer CN, Smith FJ, McLean WH, Shimizu H. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007 Feb;119(2):434-40.
237. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, Carrick T, Evans AT, Liao H, Zhao Y, Campbell LE, Schmuth M, Gruber R, Janecke AR, Elias PM, van Steensel MA, Nagtzaam I, van Geel M, Steijlen PM, Munro CS, Bradley DG, Palmer CN, Smith FJ, McLean WH, Irvine AD. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007 May;39(5):650-4.
238. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006 Jan;54(1):68-72.
239. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992 Apr;22(4):440-6.
240. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, Kapp A. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006 Feb;61(2):202-5.
241. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW, Passalacqua G. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007 Jul;120(1):164-70.
242. Aspres N, Anderson C. Malassezia yeasts in the pathogenesis of atopic dermatitis. Australas J Dermatol. 2004 Nov;45(4):199-205; quiz 6-7.
243. Mayser P, Kupfer J, Nemetz D, Schafer U, Nilles M, Hort W, Gieler U. Treatment of head and neck dermatitis with ciclopiroxolamine cream - results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2006;19(3):153-8.
244. Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res. 2006 Sep;298(4):191-9.
245. Elston DM. Status update: hospital-acquired and community-acquired methicillin-resistant Staphylococcus aureus. Cutis. 2007 Jun;79(6 Suppl):37-42.
246. Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM, White SM. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006 Dec;55(6):1003-13.
247. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother. 2007 Jun;51(6):2048-52.
248. Smith EW. Four decades of topical corticosteroid assessment. Curr Probl Dermatol. 1995;22:124-31.
249. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, Han K, Kim K, Eo SK, Lee CK. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood. 2005 May 15;105(10):3951-5.
250. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, Henz BM. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 2001 Aug;108(2):275-80.
251. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997 Sep 18;337(12):816-21.
252. Maddin S. Pimecrolimus and tacrolimus: the US FDA public health advisory. Skin Ther Lett. 2005;10(4):1-3.
253. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005 Oct;153(4):701-5.
254. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007 Apr;127(4):808-16.